Patent ID: 8758758
Filing Date: 2014-06-24
Classification: A61K,C07K

Abstract:
1. A method for the post-relapse treatment of a subject having a previously treated CD30 expressing lymphoma comprising administering to the subject a pharmaceutical composition comprising antibody-drug conjugates having formula I: or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein: Ab is an anti-CD30 antibody, S is a sulfur atom of the antibody A- is a Stretcher unit, and p is from about 2 to about 8; wherein the subject had previously been treated with CD30 targeted therapy, had discontinued treatment with the CD30 targeted therapy after achieving clinical benefit, and had subsequently relapsed, and wherein following the post-relapse treatment with the pharmaceutical composition comprising antibody-drug conjugates having formula I, the subject experiences tumor regression.